How Bristol Myers Squibb Is Accelerating Drug...

Open-weight models are closing the gap with proprietary AI — and Timothée Lacroix, cofounder and CTO of Mistral, has been betting on that since day one. In this episode, he explains why open weights accelerate enterprise adoption, how Mistral is bringing model customization into ...  Show more

Seeed Studio is a leader in open source robotics, delivering affordable NVIDIA Jetson‑powered arms that put embodied AI into the hands of millions of makers, students, and small businesses. In this episode, Seeed Studio CEO Eric Pan and Head of Robotics Elaine Wu explain how open ...  Show more

Can AI compress the years long research time of a PhD into seconds? Research scientist Max Jaderberg explores how “AI analogs” simulate real-world lab work with staggering speed and scale, unlocking new insights on protein folding and drug discovery. Drawing on his experience wor ...  Show more

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ...  Show more

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ...  Show more

In this episode of NEJM AI Grand Rounds, hosts Raj Manrai and Andy Beam interview Dr. David Ouyang, a cardiologist and AI researcher at Cedars-Sinai Medical Center. The conversation explores Ouyang’s journey from ...